Voice your opinion on congressional bill HR7828-117 and let lawmakers know your stance with UnPac!

Main Subject: Health

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

S1898-117, HR8588-117,

House floor actions Actions

IntroReferral
May. 18 2022	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
May. 18 2022	Introduced in House Introduced in House

House bill HR7828-117

To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

House bill HR7828-117

To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

Promote the cause!

Or use this QR code